[1] Narayankhedkar A, Hodiwala A, Mane A.Clinicoetiological characterization of infectious vaginitis amongst women of reproductive age group from Navi Mumbai, India[J]. J Sex Transm Dis, 2015, 2015:817092. [2] 周银娣, 温和. 阴道炎诊断的研究进展[J]. 检验医学与临床, 2014, 18:2620-2622. [3] 黄小春. 超声波臭氧雾化妇科治疗仪治疗混合性阴道炎的效果分析[J]. 当代医学, 2012, 18(15):101-102. [4] 李瑞英. 加味苦参汤外治阴道炎的临床分析[J]. 临床合理用药杂志, 2014, 18:167-168. [5] 郭姝彤, 艾彩莲, 王亚萍, 等. 阴道炎的中药治疗研究进展[J]. 陕西中医, 2015, 7: 934-935. [6] Chen Z, Zhang Z, Zhang H, et al.Analysis of the oxidative stress status in nonspecific vaginitis and its role in vaginal epithelial cells apoptosis[J]. Biomed Res Int, 2015, 2015:795656. [7] Allsworth JE, Peipert JF.Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data[J]. Obstet Gynecol, 2007, 109(1):114-120. [8] Li J, McCormick J, Bocking A, et al. Importance of vaginal microbes in reproductive health[J]. Reprod Sci, 2012, 19(3): 235-242. [9] Heczko PB, Tomusiak A, Adamski P, et al.Supplementation of standard antibiotic therapy with oral probiotics for bacterial vaginosis and aerobic vaginitis: a randomised, double-blind, placebo-controlled trial[J]. BMC Womens Health, 2015, 15:115. [10] Mastromarino P, Hemalatha R, Barbonetti A, et al.Biological control of vaginosis to improve reproductive health[J]. Indian J Med Res, 2014, 140(Suppl):S91-97. [11] 袁杰利, 赵恕, 苏显英, 等. 地衣芽胞杆菌对实验性家兔阴道炎影响的研究[J]. 中国微生态学杂志, 2006, 3(18):170-173. [12] 李新宇, 高纪伟, 徐兰芳, 等. 乳杆菌活菌对金葡菌、大肠埃希菌和白色假丝酵母菌实验性混合感染阴道炎的疗效研究[J]. 抗感染药学, 2011, 3(8):183-187. [13] Daniele M, Pascual L, Barberis L.Curative effect of the probiotic strain Lactobacillus fermentum L23 in a murine model of vaginal infection by Gardnerella vaginalis[J]. Lett Appl Microbiol, 2014, 59(1):93-98. [14] 潘展砚, 黄欣, 黄峥烨, 等. 解脲脲原体阴道炎动物模型建立及强力霉素治疗疗效观察[J]. 中国皮肤性病学杂志, 2007, 12(21):741-743. [15] Barfod KK, Roggenbuck M, Hansen LH, et al.The murine lung microbiome in relation to the intestinal and vaginal bacterial communities[J]. BMC Microbiol, 2013, 13:303. [16] Gilbert NM, Lewis WG, Lewis AL.Clinical features of bacterial vaginosis in a murine model of vaginal infection with Gardnerella vaginalis[J]. PLoS One, 2013, 8(3): e59539. [17] Hymes SR, Randis TM, Sun TY, et al.DNase inhibits Gardnerella vaginalis biofilms in vitro and in vivo[J]. J Infect Dis, 2013, 207(10):1491-1497. [18] Breshears LM, Edwards VL, Ravel J, et al.Lactobacillus crispatus inhibits growth of Gardnerella vaginalis and Neisseria gonorrhoeae on a porcine vaginal mucosa model[J]. BMC Microbiol, 2015, 15:276. [19] Castro J, Alves P, Sousa C, et al.Using an in-vitro biofilm model to assess the virulence potential of bacterial vaginosis or non-bacterial vaginosis Gardnerella vaginalis isolates[J]. Sci Rep, 2015, 5:11640. [20] Alves P, Castro J, Sousa C, et al.Gardnerella vaginalis outcompetes 29 other bacterial species isolated from patients with bacterial vaginosis, using in an in vitro biofilm formation model[J]. J Infect Dis, 2014, 210(4): 593-596. [21] 孔小锋, 陈琢. 昆明小鼠白色念珠菌性阴道炎模型构建条件的摸索[J]. 中西医结合研究, 2009, 1(5):236-240. [22] Peters BM, Yano J, Noverr MC, et al.Candida vaginitis: when opportunism knocks, the host responds[J]. PLoS Pathog, 2014, 10(4):e1003965. [23] Sobel JD, Muller G, McCormick JF. Experimental chronic vaginal candidosis in rats[J]. Sabouraudia, 1985, 23(3):199-206. [24] Fidel PL, Jr., Cutright JL, Tait L, et al. A murine model of Candida glabrata vaginitis[J]. J Infect Dis, 1996, 173(2):425-431. [25] Cassone A, Boccanera M, Adriani D, et al.Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection[J]. Infect Immun, 1995, 63(7):2619-2624. [26] De Bernardis F, Amacker M, Arancia S, et al.A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models[J]. Vaccine, 2012, 30(30):4490-4498. [27] Cassone A.Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects[J]. BJOG, 2015, 122(6):785-794. [28] De Bernardis F, Santoni G, Boccanera M, et al.Protection against rat vaginal candidiasis by adoptive transfer of vaginal B lymphocytes[J]. FEMS Yeast Res, 2010, 10(4):432-440. [29] Sandini S, La Valle R, Deaglio S, et al.A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine[J]. FEMS Immunol Med Microbiol, 2011, 62(2):215-224. [30] Fidel PL, Jr Cutright J, Steele C.Effects of reproductive hormones on experimental vaginal candidiasis[J]. Infect Immun, 2000, 68(2):651-657. [31] Fidel PL, Jr. Lynch ME, Conaway DH, et al. Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity[J]. Infect Immun, 1995, 63(2):547-553. [32] Han Y, Rhew KY.Ginsenoside Rd induces protective anti-Candida albicans antibody through immunological adjuvant activity[J]. Int Immunopharmacol, 2013, 17(3):651-657. [33] 陈雪蓉, 肖敦振, 高俊, 等. 雌激素诱导白假丝酵母菌阴道炎小鼠模型中环氧化酶-2的表达[J]. 中国妇幼保健, 2007, 33(22):4745-4748. [34] 佘晓东, 沈永年, 吕桂霞, 等. 光滑念珠菌性阴道炎小鼠模型的构建[J]. 中国麻风皮肤病杂志, 2011, 2(27):80-82. [35] 胡日新, 潘立博, 姜新, 等. 白色念珠菌与细菌混合感染小鼠阴道炎动物模型的构建及感染菌的鉴定[J]. 实验动物科学, 2014, 31(5):5-9. [36] 付瑶, 李红玉, 李淑华. 新西兰大白兔的白色念珠菌性阴道炎模型的建立[J]. 安徽农业科学, 2012, 8(40):4575-4576. [37] 徐磊, 孙玉华, 李涛, 等. 阿娜尔阴道泡腾片的药效学研究[J]. 时珍国医国药, 2008, 4(19):962-963. [38] Kissinger P.Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues[J]. BMC Infect Dis, 2015, 15: 307. [39] 白静, 胡雷, 张丽, 等. 艾叶水提物及其发酵物体内外抗阴道毛滴虫作用[J]. 中成药, 2014, 10(36):2040-2044. [40] Smith JD, Garber GE.Trichomonas vaginalis infection induces vaginal CD4+ T-cell infiltration in a mouse model: a vaccine strategy to reduce vaginal infection and HIV transmission[J]. J Infect Dis, 2015, 212(2):285-293. [41] Chatterjee A, Ratner DM, Ryan CM, et al.Anti-retroviral lectins have modest effects on adherence of trichomonas vaginalis to epithelial cells in vitro and on recovery of tritrichomonas foetus in a mouse vaginal model[J]. PLoS One, 2015, 10(8):e0135340. [42] 陈琢, 王容. 滴虫性阴道炎模型建立的实验研究[J]. 滴虫性阴道炎模型建立的实验研究, 2008, 2(37):259-261. [43] Henning T, Fakile Y, Phillips C, et al.Development of a pigtail macaque model of sexually transmitted infection/HIV coinfection using Chlamydia trachomatis, Trichomonas vaginalis, and SHIV(SF162P3)[J]. J Med Primatol, 2011, 40(4):214-223. [44] Patton DL, Sweeney YT, Agnew KJ, et al.Development of a nonhuman primate model for Trichomonas vaginalis infection[J]. Sex Transm Dis, 2006, 33(12):743-746. [45] Henning TR, Butler K, Hanson D, et al.Increased susceptibility to vaginal simian/human immunodeficiency virus transmission in pig-tailed macaques coinfected with Chlamydia trachomatis and Trichomonas vaginalis[J]. J Infect Dis, 2014, 210(8):1239-1247. [46] Smith J, Garber GE.Current status and prospects for development of a vaccine against Trichomonas vaginalis infections[J]. Vaccine, 2014, 32(14):1588-1594. [47] Cobo ER, Corbeil LB, Gershwin LJ, et al.Preputial cellular and antibody responses of bulls vaccinated and/or challenged with Tritrichomonas foetus[J]. Vaccine, 2009, 28(2):361-370. |